Payment overview · 2025
General Payments
$2,976.45
176 reported records · 36 companies
Healthcare provider profile · identity verified
Shreeniwas Lele, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MENTOR, OH · NPI 1568568426
Verified facts
What the public records show
CMS Open Payments records show Shreeniwas Lele, MD received $2,976.45 in general payments during 2025 across 176 reported records.
AstraZeneca Pharmaceuticals LP accounted for 9.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 57 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Eliquis, Farxiga, Jardiance, Mounjaro, Nurtec Odt, Ozempic, Rexulti, Rybelsus, Synthroid, Trelegy Ellipta, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 340 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synjardy by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 825 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nucala by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Trelegy Ellipta by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Caplyta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 340 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 825 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $276.90 | 9.3% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $232.38 | 7.8% | 17 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $212.12 | 7.1% | 15 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $181.86 | 6.1% | 11 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $170.61 | 5.7% | 9 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $169.21 | 5.7% | 15 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $144.20 | 4.8% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $117.48 | 4.0% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $105.13 | 3.5% | 5 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $103.12 | 3.5% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $98.33 | 3.3% | 6 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $85.98 | 2.9% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $80.15 | 2.7% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $76.58 | 2.6% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $73.14 | 2.5% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $73.12 | 2.5% | 18 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $71.97 | 2.4% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $69.29 | 2.3% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $65.14 | 2.2% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $61.05 | 2.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $56.31 | 1.9% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $55.88 | 1.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $49.93 | 1.7% | 3 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $40.11 | 1.4% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.11 | 1.3% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $38.46 | 1.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.20 | 1.1% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $31.10 | 1.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $30.64 | 1.0% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $28.50 | 1.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $26.21 | 0.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$17.88 | 0.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.76 | 0.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.79 | 0.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.07 | 0.5% | 1 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $14.74 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,891.45 | 174 |
| Education | $85.00 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $204.88 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $197.21 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $174.59 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $170.61 | 9 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $169.21 | 15 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $157.23 | 12 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $144.20 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $120.49 | 8 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $105.13 | 5 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $103.12 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $101.07 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $101.07 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $100.52 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $98.33 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $98.03 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $90.62 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $88.51 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $85.98 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $84.66 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $81.48 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $80.79 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $76.58 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $73.12 | 18 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $71.97 | 4 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $71.97 | 4 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $71.97 | 4 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $69.29 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $69.29 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $66.11 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $55.88 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $54.89 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $54.79 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $49.93 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $47.26 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.26 | 3 | 2025 |
Source payment records
|
|||||
| QSYMIA Normalized: qsymia |
Drug | VIVUS LLC | $40.11 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.11 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $38.46 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $35.78 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $31.10 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $31.10 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $30.92 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $30.64 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $28.50 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.46 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $26.21 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $25.27 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 825 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 159 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 340 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 181 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 165 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 90 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 118 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
90 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
100 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
159 | 30 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
72 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
340 | 75 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
825 | 133 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
118 | 31 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
340 | 75 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
181 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
80 | 17 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
50 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
165 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
825 | 133 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
31 | 30 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1950 | 402 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1809 | 350 |
| Amlodipine Besylate | Amlodipine Besylate | 1381 | 290 |
| Gabapentin | Gabapentin | 1217 | 218 |
| Omeprazole | Omeprazole | 1117 | 295 |
| Losartan Potassium | Losartan Potassium | 1086 | 253 |
| Metformin Hcl | Metformin Hcl | 1074 | 239 |
| Metoprolol Succinate | Metoprolol Succinate | 978 | 235 |
| Furosemide | Furosemide | 946 | 228 |
| Sertraline Hcl | Sertraline Hcl | 883 | 131 |
| Potassium Chloride | Potassium Chloride | 870 | 198 |
| Trazodone Hcl | Trazodone Hcl | 861 | 161 |
| Eliquis | Apixaban | 825 | 133 |
| Metoprolol Tartrate | Metoprolol Tartrate | 773 | 156 |
| Tamsulosin Hcl | Tamsulosin Hcl | 730 | 181 |
| Lisinopril | Lisinopril | 729 | 139 |
| Pantoprazole Sodium | Pantoprazole Sodium | 718 | 164 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 499 | 188 |
| Glipizide | Glipizide | 479 | 94 |
| Divalproex Sodium | Divalproex Sodium | 462 | 49 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 449 | 87 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 438 | 132 |
| Clopidogrel | Clopidogrel Bisulfate | 408 | 86 |
| Doxycycline Hyclate | Doxycycline Hyclate | 397 | 253 |
| Januvia | Sitagliptin Phosphate | 387 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 384 | 80 |
| Jardiance | Empagliflozin | 340 | 75 |
| Donepezil Hcl | Donepezil Hcl | 338 | 53 |
| Mirtazapine | Mirtazapine | 338 | 62 |
| Carvedilol | Carvedilol | 328 | 59 |
| Quetiapine Fumarate | Quetiapine Fumarate | 327 | 53 |
| Memantine Hcl | Memantine Hcl | 322 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 316 | 68 |
| Duloxetine Hcl | Duloxetine Hcl | 312 | 56 |
| Buspirone Hcl | Buspirone Hcl | 301 | 50 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 291 | 190 |
| Prednisone | Prednisone | 279 | 153 |
| Levetiracetam | Levetiracetam | 269 | 39 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 265 | 175 |
| Benztropine Mesylate | Benztropine Mesylate | 249 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 248 | 99 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 247 | 92 |
| Allopurinol | Allopurinol | 243 | 46 |
| Simvastatin | Simvastatin | 242 | 47 |
| Spironolactone | Spironolactone | 241 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 238 | 52 |
| Fluoxetine Hcl | Fluoxetine Hcl | 235 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 232 | 41 |
| Famotidine | Famotidine | 227 | 52 |
| Montelukast Sodium | Montelukast Sodium | 227 | 62 |
| Olanzapine | Olanzapine | 227 | 29 |
| Risperidone | Risperidone | 206 | 23 |
| Aripiprazole | Aripiprazole | 204 | 25 |
| Nabumetone | Nabumetone | 198 | 92 |
| Ondansetron Hcl | Ondansetron Hcl | 192 | 97 |
| Humalog Kwikpen U-100 | Insulin Lispro | 187 | 43 |
| Ropinirole Hcl | Ropinirole Hcl | 185 | 35 |
| Mounjaro | Tirzepatide | 181 | 32 |
| Ibuprofen | Ibuprofen | 176 | 58 |
| Hydralazine Hcl | Hydralazine Hcl | 175 | 32 |
| Levofloxacin | Levofloxacin | 173 | 135 |
| Nystatin | Nystatin | 168 | 93 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 167 | 60 |
| Atenolol | Atenolol | 165 | 30 |
| Ozempic | Semaglutide | 165 | 30 |
| Clonidine Hcl | Clonidine Hcl | 161 | 35 |
| Sucralfate | Sucralfate | 161 | 38 |
| Farxiga | Dapagliflozin Propanediol | 159 | 30 |
| Alendronate Sodium | Alendronate Sodium | 153 | 33 |
| Baclofen | Baclofen | 151 | 20 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 150 | 55 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 149 | 41 |
| Amitriptyline Hcl | Amitriptyline Hcl | 142 | 38 |
| Lactulose | Lactulose | 141 | 32 |
| Meclizine Hcl | Meclizine Hcl | 135 | 46 |
| Paroxetine Hcl | Paroxetine Hcl | 132 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 132 | 33 |
| Torsemide | Torsemide | 131 | 33 |
| Glimepiride | Glimepiride | 128 | 30 |
| Finasteride | Finasteride | 125 | 28 |
| Humalog | Insulin Lispro | 125 | 24 |
| Midodrine Hcl | Midodrine Hcl | 125 | 26 |
| Azithromycin | Azithromycin | 118 | 92 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 118 | 31 |
| Xarelto | Rivaroxaban | 118 | 26 |
| Lorazepam | Lorazepam | 117 | 30 |
| Latanoprost | Latanoprost | 112 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 108 | 27 |
| Tramadol Hcl | Tramadol Hcl | 106 | 30 |
| Haloperidol | Haloperidol | 104 | 27 |
| Lamotrigine | Lamotrigine | 101 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 100 | 23 |
| Methocarbamol | Methocarbamol | 100 | 31 |
| Myrbetriq | Mirabegron | 100 | 14 |
| Warfarin Sodium | Warfarin Sodium | 99 | 26 |
| Ezetimibe | Ezetimibe | 98 | 21 |
| Bupropion Hcl Sr | Bupropion Hcl | 95 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 93 | 20 |
| Synthroid | Levothyroxine Sodium | 90 | 27 |
| Fluconazole | Fluconazole | 87 | 53 |
| Bupropion Xl | Bupropion Hcl | 86 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 86 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 86 | 15 |
| Clozapine | Clozapine | 82 | suppressed |
| Topiramate | Topiramate | 82 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 81 | 50 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 80 | 12 |
| Cephalexin | Cephalexin | 80 | 48 |
| Klor-Con M20 | Potassium Chloride | 80 | 35 |
| Trulicity | Dulaglutide | 80 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 79 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 78 | 25 |
| Ofloxacin | Ofloxacin | 78 | 64 |
| Meloxicam | Meloxicam | 77 | 20 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 76 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 74 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 72 | 18 |
| Metronidazole | Metronidazole | 68 | 57 |
| Budesonide | Budesonide | 67 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 67 | 30 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 67 | 12 |
| Prazosin Hcl | Prazosin Hcl | 67 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 65 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 65 | 20 |
| Propranolol Hcl | Propranolol Hcl | 65 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 64 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 62 | 37 |
| Digoxin | Digoxin | 59 | suppressed |
| Fenofibrate | Fenofibrate | 59 | suppressed |
| Ondansetron Odt | Ondansetron | 59 | 31 |
| Oxcarbazepine | Oxcarbazepine | 59 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 58 | 32 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 58 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 38 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 56 | 22 |
| Enoxaparin Sodium | Enoxaparin Sodium | 56 | 20 |
| Phenobarbital | Phenobarbital | 55 | suppressed |
| Vraylar | Cariprazine Hcl | 55 | suppressed |
| Colchicine | Colchicine | 54 | 25 |
| Celecoxib | Celecoxib | 53 | 30 |
| Dutasteride | Dutasteride | 53 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 52 | suppressed |
| Hydrocortisone | Hydrocortisone | 51 | 26 |
| Brimonidine Tartrate | Brimonidine Tartrate | 50 | suppressed |
| Entresto | Sacubitril/Valsartan | 50 | 13 |
| Fenofibrate | Fenofibrate,micronized | 50 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 17 |
| Ziprasidone Hcl | Ziprasidone Hcl | 50 | suppressed |
| Ketoconazole | Ketoconazole | 49 | 28 |
| Ingrezza | Valbenazine Tosylate | 48 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 48 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 47 | 39 |
| Metformin Hcl Er | Metformin Hcl | 47 | 14 |
| Nitroglycerin | Nitroglycerin | 47 | 32 |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 47 | suppressed |
| Primidone | Primidone | 47 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 47 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 47 | 16 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 45 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | suppressed |
| Rybelsus | Semaglutide | 45 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | suppressed |
| Carbamazepine | Carbamazepine | 44 | suppressed |
| Clonazepam | Clonazepam | 44 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 43 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 42 | 24 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 41 | suppressed |
| Lacosamide | Lacosamide | 41 | suppressed |
| Lidocaine | Lidocaine | 41 | 15 |
| Haloperidol Lactate | Haloperidol Lactate | 40 | suppressed |
| Nifedipine Er | Nifedipine | 40 | suppressed |
| Pregabalin | Pregabalin | 40 | suppressed |
| Tradjenta | Linagliptin | 40 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 39 | suppressed |
| Mresvia | Rsv Vaccine, Pref, Mrna/Pf | 39 | 39 |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 15 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 36 | 21 |
| Galantamine Hbr | Galantamine Hbr | 36 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 36 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Brilinta | Ticagrelor | 35 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 34 | 26 |
| Sevelamer Carbonate | Sevelamer Carbonate | 34 | suppressed |
| Timolol Maleate | Timolol Maleate | 34 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 34 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 34 | suppressed |
| Glipizide Er | Glipizide | 33 | suppressed |
| Ramipril | Ramipril | 33 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 19 |
| Erythromycin | Erythromycin Base | 32 | 25 |
| Mupirocin | Mupirocin | 32 | 15 |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 32 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 31 | 20 |
| Diazepam | Diazepam | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 31 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 31 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 30 |
| Zonisamide | Zonisamide | 31 | suppressed |
| Carbamazepine Er | Carbamazepine | 30 | suppressed |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 30 | 11 |
| Novolog Flexpen | Insulin Aspart | 30 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 30 | suppressed |
| Ranolazine Er | Ranolazine | 30 | suppressed |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Ibu | Ibuprofen | 29 | 17 |
| Incruse Ellipta | Umeclidinium Bromide | 29 | suppressed |
| Klayesta | Nystatin | 29 | 20 |
| Methimazole | Methimazole | 29 | suppressed |
| Novolog | Insulin Aspart | 29 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 28 | suppressed |
| Fanapt | Iloperidone | 28 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 28 | suppressed |
| Perseris | Risperidone | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 22 |
| Sodium Chloride | 0.9 % Sodium Chloride | 25 | 17 |
| Tivicay | Dolutegravir Sodium | 25 | suppressed |
| Tobramycin | Tobramycin | 25 | 19 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | 12 |
| Cilostazol | Cilostazol | 24 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 24 | suppressed |
| Trospium Chloride | Trospium Chloride | 24 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Amantadine | Amantadine Hcl | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Caplyta | Lumateperone Tosylate | 23 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 23 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 23 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 23 | 11 |
| Acyclovir | Acyclovir | 22 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 22 | 17 |
| Lovastatin | Lovastatin | 22 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 22 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 22 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 21 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 21 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 21 | 11 |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 20 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 20 | suppressed |
| Briviact | Brivaracetam | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Ertapenem | Ertapenem Sodium | 17 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 17 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Trifluoperazine Hcl | Trifluoperazine Hcl | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | 11 |
| Clobazam | Clobazam | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 16 | suppressed |
| Glucagon Emergency Kit | Glucagon | 16 | suppressed |
| Nyamyc | Nystatin | 16 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 16 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 16 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | 12 |
| Asenapine Maleate | Asenapine Maleate | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 14 | 12 |
| Hydroxyurea | Hydroxyurea | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Lamotrigine Odt | Lamotrigine | 14 | suppressed |
| Nexium | Esomeprazole Magnesium | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Paliperidone Er | Paliperidone | 14 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Cefazolin Sodium | Cefazolin Sodium | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 13 | suppressed |
| Epidiolex | Cannabidiol (Cbd) | 13 | suppressed |
| Humira Pen | Adalimumab | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Meropenem | Meropenem | 13 | suppressed |
| Nucala | Mepolizumab | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Olanzapine Odt | Olanzapine | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Imipenem-Cilastatin Sodium | Imipenem/Cilastatin Sodium | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 12 | suppressed |
| Procrit | Epoetin Alfa | 12 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Ampicillin-Sulbactam | Ampicillin Sod/Sulbactam Sod | 11 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Dalfampridine Er | Dalfampridine | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 11 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 11 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl In 5 % Dextrose | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,976.45 · 176 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AFREZZA, AIRSUPRA, AREXVY, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, COBENFY, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, GVOKE HYPOPEN, JARDIANCE, Korlym, LEQVIO, MINIMED 780G, MOUNJARO, NURTEC ODT, Natroba, OTEZLA, Omnipod, Ozempic, PREVNAR 20, PROLIA, QSYMIA, QULIPTA, RECORLEV, REPATHA, REXULTI, Rybelsus, SHINGRIX, SYNTHROID, Spinosad, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, WATCHMAN FLX, WaveWriter Alpha Prime 16, YUPELRI, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 28 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error